Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Treatment and Management of Myelodysplastic Syndrome (MDS) requires a coordinated approach that blends accurate diagnosis, risk assessment, and a spectrum of therapeutic options. This page is designed for patients, families, and international visitors who are seeking clear guidance on how MDS is treated and managed at a world‑class facility. According to recent hematology registries, approximately 10,000 new cases of MDS are diagnosed each year in Europe, underscoring the importance of timely, personalized care.
Liv Hospital’s hematology team combines JCI‑accredited standards with cutting‑edge research to deliver a full continuum of care—from initial laboratory work‑up to advanced stem‑cell transplantation. Whether you are newly diagnosed or navigating disease progression, understanding the available treatment and management pathways empowers you to make informed decisions aligned with your health goals.
In the sections that follow, we will examine the diagnostic framework, core therapeutic modalities, disease‑modifying and emerging treatments, personalized planning, and long‑term follow‑up strategies. Each segment includes practical lists or comparison tables to help you visualize the options and their relative benefits.
Accurate diagnosis is the foundation of effective treatment and management. MDS is identified through a combination of peripheral blood analysis, bone‑marrow examination, and cytogenetic testing. The International Prognostic Scoring System (IPSS‑R) categorizes patients into risk groups that guide therapeutic intensity.
These data points enable the hematology team at Liv Hospital to tailor the treatment and management plan to the individual’s disease biology and overall health status.
For many patients, especially those in lower‑risk categories, the primary goal is to maintain quality of life while minimizing disease‑related complications. Core supportive measures form the backbone of early treatment and management strategies.
Hematopoietic growth factors can reduce transfusion requirements and improve blood counts:
These interventions are often combined with regular monitoring to adjust dosing and avoid overtreatment. In Liv Hospital’s international patient program, nursing coordinators ensure that transfusion schedules and growth‑factor regimens are synchronized with the patient’s travel itinerary and local healthcare resources.
When disease‑related cytopenias become refractory to supportive care, disease‑modifying therapies are introduced to alter the natural history of MDS. The choice among hypomethylating agents, immunomodulatory drugs, and allogeneic stem‑cell transplantation depends on risk category, genetic profile, and patient fitness.
Allogeneic hematopoietic stem‑cell transplantation (HSCT) remains the only potentially curative option. Eligibility criteria typically include:
Liv Hospital’s transplant unit offers reduced‑intensity conditioning protocols that expand eligibility to older or comorbid patients, while maintaining graft‑versus‑leukemia effect.
Research in MDS is rapidly evolving, with several novel agents showing promise in early‑phase trials. Incorporating these options into the treatment and management plan can be especially valuable for patients with refractory disease or specific molecular abnormalities.
International patients benefit from Liv Hospital’s dedicated research liaison team, which assists with:
Participating in a trial may provide access to cutting‑edge drugs before they become widely available, aligning with a proactive treatment and management philosophy.
Effective treatment and management of MDS is highly individualized. The multidisciplinary team evaluates a matrix of clinical variables to construct a plan that balances efficacy, safety, and patient preferences.
Liv Hospital employs a structured consultation model:
This collaborative approach ensures that the chosen treatment and management pathway aligns with the patient’s values and circumstances.
After initiating therapy, vigilant follow‑up is essential to assess response, detect complications, and adjust the plan as needed. Long‑term survivorship care also addresses psychosocial well‑being and preventive health.
Patients who achieve remission or stable disease benefit from lifestyle interventions that support hematologic health:
Liv Hospital’s international patient services coordinate follow‑up appointments with local providers when patients return to their home countries, ensuring continuity of care throughout the entire treatment and management journey.
Liv Hospital combines JCI accreditation, a multilingual care team, and a 360‑degree international patient program to deliver seamless treatment and management for Myelodysplastic Syndrome. Our state‑of‑the‑art hematology department offers personalized care plans, access to clinical trials, and world‑class stem‑cell transplantation—all supported by dedicated logistics, interpreter services, and comfortable accommodation options for patients traveling from abroad.
Ready to discuss your personalized Myelodysplastic Syndrome care plan? Contact Liv Hospital today to schedule a virtual consultation and learn how our expert team can guide you through every step of treatment and management.
Liv Hospital Vadistanbul
Prof. MD. Itır Şirinoğlu Demiriz
Hematology
Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan
Pediatric Hematology and Oncology
Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun
Pediatric Hematology and Oncology
Liv Hospital Ankara
Assoc. Prof. MD. Ramazan Öcal
Hematology
Liv Hospital Ankara
Prof. MD. Meral Beksaç
Hematology
Liv Hospital Ankara
Prof. MD. Oral Nevruz
Hematology
Liv Hospital Gaziantep
Assoc. Prof. MD. Fadime Ersoy Dursun
Hematology
Spec. MD. Ceyda Aslan
Hematology
Spec. MD. Elmir İsrafilov
Hematology
Spec. MD. Minure Abışova Eliyeva
Hematology
Liv Hospital Ulus + Liv Hospital Bahçeşehir
Prof. MD. Mehmet Hilmi Doğu
Hematology
Send us all your questions or requests, and our expert team will assist you.
Diagnosis of Myelodysplastic Syndrome relies on a combination of laboratory and pathology studies. A complete blood count (CBC) with differential identifies cytopenias. Bone‑marrow aspiration and biopsy provide morphological assessment and cellularity. Flow cytometry helps characterize immunophenotype, while cytogenetic karyotyping detects chromosomal abnormalities. Next‑generation sequencing can uncover gene mutations that influence prognosis and therapeutic choices. Together these tests allow accurate classification and risk assessment.
The International Prognostic Scoring System – Revised (IPSS‑R) assigns points for three parameters: percentage of bone‑marrow blasts, cytogenetic risk category, and depth of cytopenias (hemoglobin, platelets, neutrophils). Summing these points places patients into five risk levels. Very Low risk patients have a median survival >8 years, while Very High risk patients have a median survival of less than one year. This stratification guides therapeutic intensity, from supportive care in low‑risk disease to disease‑modifying agents or transplant in high‑risk cases.
For low‑risk MDS, the primary goal is to maintain quality of life. Red blood cell transfusions alleviate anemia‑related fatigue, while platelet transfusions prevent bleeding. Chronic transfusion dependence may require iron chelation to reduce organ toxicity. Prophylactic antibiotics protect neutropenic patients, and annual influenza and pneumococcal vaccinations lower infection risk. Growth factors such as erythropoiesis‑stimulating agents, G‑CSF, and thrombopoietin mimetics can reduce transfusion needs and improve blood counts.
Allogeneic hematopoietic stem‑cell transplantation (HSCT) remains the only potentially curative option for MDS. Candidates are usually those classified as intermediate‑, high‑, or very high risk by IPSS‑R, have a matched sibling or unrelated donor, and possess acceptable cardiac, pulmonary, and hepatic function. Age alone is not an absolute barrier; physiological fitness is more important. Liv Hospital uses reduced‑intensity conditioning protocols to extend eligibility to older or comorbid patients while preserving graft‑versus‑leukemia effect.
Research in MDS is rapidly evolving. Spliceosome inhibitors such as H3B‑8800 target SF3B1 mutations. Immune checkpoint inhibitors like pembrolizumab are studied in high‑risk disease to boost anti‑tumor immunity. Anti‑CD47 antibodies aim to enhance phagocytosis of malignant cells. Combination regimens pairing hypomethylating agents with the BCL‑2 inhibitor venetoclax have shown promising response rates. Participation in these trials at Liv Hospital provides access to cutting‑edge drugs before they become standard of care.
Liv Hospital follows a structured shared‑decision‑making model. After reviewing diagnostic data and IPSS‑R risk, the team discusses all therapeutic options, outlining benefits and risks. They consider patient‑specific factors such as physiological age, cytogenetic/molecular profile, existing comorbidities, and personal goals (curative vs. quality‑of‑life). Social logistics, travel plans, and financial considerations are also addressed. The outcome is a written, patient‑approved care plan that aligns with the individual’s values and circumstances.
Post‑treatment monitoring is critical to assess response and detect complications. During active therapy, a complete blood count is performed every 2–4 weeks. After 4–6 cycles of hypomethylating agents, a repeat bone‑marrow biopsy evaluates morphological response. Ongoing cytogenetic and molecular analyses track clonal evolution. Renal and hepatic panels are checked before each chemotherapy cycle. Survivorship care includes lifestyle counseling, vaccination updates, and psychosocial support, with coordination of local follow‑up for international patients.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 42 01